Importing Cosmetics into the US: MoCRA Responsibilities and Supplier Documentation

To import cosmetics into the US, confirm product classification, map applicable MoCRA responsibilities, and obtain supplier safety, labeling and manufacturing records before placing an order.

Identify the product category before assessing MoCRA obligations

US cosmetics import planning starts with checking the product’s intended use, claims and ingredients against FDA classification guidance. Confirm whether the product falls within the cosmetic framework, a drug framework or both before setting supplier documentation requirements.

The Modernization of Cosmetics Regulation Act of 2022, commonly called MoCRA, is central to cosmetics compliance planning. However, applicability, exemptions, implementation schedules and related FDA rules should be checked against current official guidance rather than assumed from a supplier’s previous exports.

Review claims as well as the formula

A moisturizer, acne treatment and sunscreen should not automatically receive the same regulatory checklist. Therapeutic claims or claims affecting body structure or function can change the classification analysis, even when products share packaging or ingredients.

Request the complete proposed US presentation:

• Product and variant names, including shades and fragrances.
• Packaging artwork, inserts and directions.
• Website, advertising and retailer product-page claims.
• Full ingredient composition and intended uses.

Ask a qualified US regulatory adviser to assess borderline products before approving artwork or paying a production deposit. Start with FDA’s guidance on cosmetics versus drugs.

Separate regulatory classification from customs classification

FDA product status and the customs tariff classification answer different questions. Neither an HS Code nor a supplier’s description of a product as “beauty care” resolves its regulatory status.

Have your customs broker assess the applicable US tariff classification, origin, valuation and entry data separately. Confirm current entry requirements with US Customs and Border Protection and FDA’s cosmetics import guidance.

Buying decision: Resolve classification before comparing landed costs. A low quotation is not commercially comparable if it assumes the wrong regulatory pathway.

Map the responsible person, facility and importer roles

The named responsible person, manufacturing facility and importer should be mapped separately because their functions are not interchangeable. Confirm each party’s applicable duties under current FDA guidance and document the operational handoffs before contracting.

FDA’s MoCRA framework identifies the responsible person by reference to the manufacturer, packer or distributor whose name appears on the label. For a private-label import, determine how that definition applies to the proposed label rather than assuming the overseas factory holds every compliance duty.

Use a responsibility matrix before supplier approval

The following matrix is a due-diligence tool, not a legal determination of your company’s obligations. Validate the allocation against FDA’s MoCRA resources, the actual supply chain and qualified advice.

Role or workstream	Applicability question to resolve	Evidence to request	Procurement risk
Named responsible person	Which label-named entity fits FDA’s definition?	Final artwork, legal entity details and agreed responsibility map	Brand owner and factory each assume the other is responsible
Manufacturing or processing facility	Is registration applicable to each relevant site?	Site identity, registration evidence where applicable, or documented exemption analysis	Records identify a trading company rather than the production site
Foreign facility US agent	Is a US agent designation applicable and properly maintained?	Agent contact details and confirmation of the arrangement	Agent role is confused with importer or responsible-person duties
Product listing	Who handles applicable submissions, updates and product coverage?	Submission records and a product-to-record mapping	New variants or changed products are omitted
Safety substantiation	Who ensures adequate support and access to records?	Safety assessment, supporting studies and record-access terms	Supplier provides only an SDS
Adverse events and corrective action	Who receives, assesses and escalates complaints?	Procedures, contacts, reporting workflow and batch traceability	A safety complaint stalls between commercial parties
Customs entry	Who manages import entry and supporting data?	Broker instructions, invoice data and entry-document responsibilities	Commercial and regulatory descriptions conflict

Test exemptions rather than accepting them verbally

MoCRA includes exemptions whose availability depends on the business and product circumstances. Ask the supplier to identify the basis for any claimed exemption, the activities and products it covers, and who reviewed the conclusion.

A facility-registration or product-listing exemption should not be treated as a blanket exemption from all applicable obligations. Confirm the scope through FDA’s current guidance and qualified advice, especially where the product has characteristics that may affect exemption eligibility.

Warning: Registration or listing evidence is not proof of FDA approval, product safety or compliant labeling. Treat supplier claims such as “FDA-certified cosmetics” as a prompt for further investigation.

Build a supplier dossier that supports a real safety assessment

A useful cosmetics supplier dossier connects the finished formula, production site, packaging and safety evidence to the exact product being purchased. Collect records that support review and ongoing access, rather than accepting a generic certificate pack.

Formula and safety documentation

Request a full quantitative formula under appropriate confidentiality arrangements, together with ingredient identities, functions and relevant specifications. A label ingredient list alone may not provide enough information for a qualified safety reviewer.

The evidence needed depends on the product’s formulation, exposure, users and packaging. Ask the reviewer to identify gaps in areas such as:

• Toxicological support for ingredients and finished-product use.
• Microbiological quality and preservative effectiveness, where relevant.
• Stability and packaging compatibility.
• Impurities, contaminants and restricted-ingredient screening.
• Support for warnings, directions and claimed performance.

An SDS addresses a different documentation purpose and should not substitute for cosmetic safety substantiation. A batch certificate of analysis likewise shows results for specified tests; it does not establish the adequacy of the overall safety assessment.

Manufacturing and batch records

Identify the actual manufacturing, filling and packing sites, including subcontractors. Request documented specifications, batch-release criteria, traceability procedures and available evidence of manufacturing controls.

Check FDA’s current position on cosmetic good manufacturing practice requirements and implementation before making contractual compliance statements. Separately, define practical quality expectations such as sanitation controls, deviation handling, retained samples and nonconforming-batch disposition.

For testing reports, match the sample identity, formula version, method, laboratory and acceptance criteria to the intended US product. If a supplier relies on an older report or a related formulation, ask the safety reviewer whether that evidence is transferable.

Confidential access without losing control

Suppliers may legitimately protect formulations and proprietary studies. Arrange access through a nondisclosure agreement, controlled data room or qualified third-party reviewer, while confirming that necessary records can be made available for applicable regulatory purposes.

A commercial assurance that “documents exist” is not equivalent to usable access. Put retrieval arrangements, contacts and response expectations in the supply agreement.

Verify registration, listing and labeling before shipment

Registration, product listing and labeling should be checked as distinct workstreams against the proposed US sale. Their records must correspond to the actual entities, facilities, formulations and packaging involved.

Registration and listing evidence

Use FDA’s facility registration and product listing guidance to verify applicability, submission methods, maintenance requirements and available exemptions.

Where applicable, request submission evidence and establish who handles corrections, renewals or updates. Do not assume every record is publicly searchable or that a registration identifier authenticates the supplier presenting it.

Cross-check legal names and site addresses against contracts and manufacturing documentation. Investigate unexplained discrepancies before releasing the order.

Label and ingredient review

Have a qualified reviewer assess the final US artwork, not just a supplier’s international label template. Review ingredient declarations, identity, quantity statements, business identification, warnings and applicable contact information against current FDA guidance.

Ingredient restrictions and color-additive conditions also need product-specific review. Direct these checks to FDA’s official cosmetics labeling resources and relevant ingredient or color-additive guidance.

Avoid approving claims merely because a competitor uses them. The intended use communicated across packaging and digital channels should remain consistent with the classification assessment.

Turn compliance gaps into RFQ and contract decisions

A strong cosmetics RFQ makes documentation readiness part of supplier selection rather than a post-order request. The purchase agreement should then convert accepted evidence and unresolved gaps into clear release conditions.

Step-by-step importer checklist

• Define the product: List intended use, claims, users, variants, packaging and target US channels.
• Confirm the pathway: Obtain a classification assessment and identify regulatory questions requiring official guidance.
• Map entities: Identify the seller, actual production sites, label-named entity, importer and relevant contacts.
• Assess MoCRA applicability: Record the reasoning for registration, listing and exemption conclusions.
• Review the dossier: Have a qualified reviewer assess formula access, safety evidence and testing gaps.
• Approve artwork: Check the exact US label and associated marketing claims.
• Set commercial conditions: Agree MOQ, lead time, testing costs, document access and change-control terms.
• Plan the entry: Confirm tariff classification, origin, valuation and entry information with the broker.
• Release the shipment: Match batch records, specifications, artwork and shipping documents to the approved order.
• Prepare post-sale controls: Test complaint escalation, traceability and corrective-action workflows.

Contract for changes and post-sale cooperation

Require advance notice of changes to formula, ingredient sources, production sites, packaging or specifications. State which changes need buyer approval and renewed technical review before shipment.

Allocate costs and cooperation for investigation, rejected goods, withdrawal or recall without assuming the contract can transfer statutory responsibility. Verify applicable adverse-event reporting and recordkeeping rules with FDA, then build internal escalation times that support those obligations.

Use a named place and an appropriate Incoterms 2020 rule in the quotation. Incoterms allocate specified delivery responsibilities, costs and risks; they do not establish cosmetic compliance or replace a regulatory responsibility agreement.